Telomir Pharmaceuticals, Inc. - Common Stock, no par value (TELO)

CUSIP: 87975F104

Q3 2024 13F Holders as of 30 Sep 2024

Holder snapshot 6 signals
Share change
+1,402,806
SEC-reported price per share
$6.42
Number of holders
33
Value change
+$9,006,860
Number of buys
20
Number of sells
5
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
68,772,896

Security key

87975F104

Report period

Q3 2024

Institutions

33

Top holders

10

Ownership snapshot

Top reported holders of TELO - Telomir Pharmaceuticals, Inc. - Common Stock, no par value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
Christopher Chapman MD
Disclosed value leader
Christopher Chapman MD
Comparable rows
0/15
Latest evidence
27 Aug 2024
3/4/5 13F Highest disclosed value: $6,048,782 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

Christopher Chapman MD has the largest disclosed position value at $6.05M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Christopher Chapman MD's linked filing trail.
Disclosed position value Top 5
Christopher Chapman MD $6.05M
Craig Eagle $3.02M
Nathen Fuentes $627K
BlackRock Finance, Inc. $422.8K
GEODE CAPITAL MANAGEMENT, LLC $319.2K

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
Christopher Chapman MD
3/4/5
CEO & Chairman, Director
—
denominator unverified
$6,048,782
975,610 shares
— 08 Feb 2024
Craig Eagle
3/4/5
Director
—
denominator unverified
$3,024,391
487,805 shares
— 08 Feb 2024
Nathen Fuentes
3/4/5
Chief Financial Officer
—
denominator unverified
$627,031
101,134 shares
— 08 Feb 2024
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$422,794
87,899 shares
— 30 Jun 2024
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
13F
—
denominator unverified
$319,167
66,355 shares
— 30 Jun 2024
Bradley Kroenig
3/4/5
Director
—
denominator unverified
$302,442
48,781 shares
— 08 Feb 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q3 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Institutions
33
Shares
2,045,931
Rows available
33
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Compare Q3 2024 vs Q2 2026 Across Filers

Q2 2026 holders
32
Q3 2024 holders
33
Holder diff
1
Investor Q2 2026 Shares Q3 2024 Shares Share Diff Share Chg % Q2 2026 value Q3 2024 value Value change Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .